Your browser doesn't support javascript.
loading
The nightmare severity index (NSI): A short new multidimensional tool for assessing nightmares.
Geoffroy, Pierre A; Stern, Emilie; Maruani, Julia; Cornic, Renaud; Bazin, Balthazar; Clerici, Emmanuelle; Ambar Akkaoui, Marine; Lopez, Régis; Frija Masson, Justine; d'Ortho, Marie-Pia; Lejoyeux, Michel; Micoulaud Franchi, Jean-Arthur; Couffignal, Camille.
  • Geoffroy PA; Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.
  • Stern E; Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France.
  • Maruani J; NeuroDiderot, Inserm, FHU I2-D2, Université Paris Cité, Paris, France.
  • Cornic R; Institute for Cellular and Integrative Neurosciences, CNRS UPR 3212, Strasbourg, France.
  • Bazin B; Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France.
  • Clerici E; Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.
  • Ambar Akkaoui M; Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France.
  • Lopez R; NeuroDiderot, Inserm, FHU I2-D2, Université Paris Cité, Paris, France.
  • Frija Masson J; Département d'Epidémiologie, Biostatistique et Recherche Clinique AP-HP, DMU PRISME, Hôpital Bichat - Claude Bernard, Paris, France.
  • d'Ortho MP; Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.
  • Lejoyeux M; Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France.
  • Micoulaud Franchi JA; NeuroDiderot, Inserm, FHU I2-D2, Université Paris Cité, Paris, France.
  • Couffignal C; Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France.
J Sleep Res ; : e14065, 2023 Oct 17.
Article en En | MEDLINE | ID: mdl-37846776
ABSTRACT
This psychometric pilot study aims to evaluate a new multidimensional simple scale, named the nightmare severity index (NSI) - close to the existing insomnia (ISI) and hypersomnia (HSI) severity indexes. The NSI encompasses all main dimensions of nightmare disorder, evaluating four subdimensions frequency, emotional impact, diurnal impact, and nocturnal impact of nightmares. The NSI was completed by a total of 102 patients. The majority of the population consisted of women (64%) and outpatient individuals (76%) diagnosed with mood disorders such as depression (31%) and bipolar disorder (41%). Comorbidity with post-traumatic stress disorder (PTSD) was prevalent (44%), and psychotropic medications were commonly used (47%). Internal validity analyses indicated that the NSI was well suited for exploratory factor analysis. All items demonstrated satisfactory correlations with the factors, and the questionnaire exhibited good internal consistency (Cronbach's alpha >0.7). Higher NSI scores were observed among individuals experiencing nightmare symptoms considering the DSM-5/ICSD-3 criteria. In summary, the NSI proves to be a promising and valuable tool for clinical practice, demonstrating good acceptability, internal validity, and the ability to assess nightmare severity.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article